Dianthus Therapeutics (DNTH) Non-Current Assets (2017 - 2025)

Dianthus Therapeutics' Non-Current Assets history runs 9 years deep, the most recent figure standing at $121.5 million for Q4 2025.

• On a quarterly basis, Non-Current Assets rose 30.48% year-over-year to $121.5 million in Q4 2025; TTM through Dec 2025 was $425.2 million, a 158.19% increase from a year earlier, with the FY2025 full-year figure at $121.5 million, up 30.48% from the prior year.
• Non-Current Assets fell to $121.5 million in Q4 2025 per DNTH's latest filing, from $163.6 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $163.6 million in Q3 2025 and bottomed at $1.0 million in Q3 2023.
• The 5-year median for Non-Current Assets is $21.1 million (2021), against an average of $40.7 million.
• Across the five-year window, Non-Current Assets sank 96.85% in 2023 and surged 6516.35% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $9.2 million in 2021, then plunged by 88.35% to $1.1 million in 2022, then surged by 81.43% to $2.0 million in 2023, then surged by 4664.79% to $93.1 million in 2024, then surged by 30.48% to $121.5 million in 2025.
• Per Business Quant, the three latest DNTH Non-Current Assets figures stand at $121.5 million (Q4 2025), $163.6 million (Q3 2025), and $62.5 million (Q2 2025).